赛升药业 (300485)

Beijing Science Sun Pharmaceutical Co.,LTD.

ASZ

Tags

Venture Capital ConceptInnovative DrugsPharmaceutical ManufacturingNon-GAAP LossesBiological VaccinesHepatitis ConceptAssisted Reproduction

K-Line Chart

No K-line data

Stock Details

1. Key Indicators

  • Total Shares(W): 48166.64
  • Circulating A-Shares(W): 27381.72
  • Earnings Per Share(RMB): 0.1100
  • Net Assets Per Share(RMB): 7.0766
  • Operating Revenue(W RMB): 30862.71
  • Total Profit(W RMB): 5919.54
  • Net Profit Attributable to Parent(W RMB): 5185.96
  • Net Profit Growth Rate(%): 152.81
  • Weighted Return on Equity(%): 1.5300
  • Operating Cash Flow Per Share(RMB): 0.0630
  • Undistributed Profit Per Share(RMB): 3.8102
  • Capital Reserve Per Share(RMB): 1.7563

2. Main Business

The main business covers:

  • Research, production and sales of injection preparations

3. Company Basic Information

  • Company Name: Beijing Science Sun Pharmaceutical Co., Ltd.
  • Listing Date: 2015-06-26
  • Industry: Pharmaceutical Manufacturing
  • Address: No. 8 Xingsheng Street, Beijing Economic-Technological Development Area, Beijing, China
  • Website: www.ssyy.com.cn
  • Company Profile: On July 21, 1998, the Beijing Pharmaceutical Administration issued document ([98] Jing Yi Yao Ju Gui Bu Zi No. 019) approving the establishment of Saisheng Pharmaceutical by the Biochemical Factory, Shenyang Sainuo, and the Pharmaceutical Group. On June 28, 2011, a resolution was passed at the shareholders' meeting of Saisheng Pharmaceutical, with all shareholders agreeing to act as promoters to transform the company into a joint stock limited company and rename it as Beijing Science Sun Pharmaceutical Co., Ltd. On July 28, 2011, the issuer completed the change of registration with the Beijing Administration for Industry and Commerce and obtained the business license with registration number 110302000409597.

4. Top 10 Circulating Shareholders

Rank Institution Name Institution Type Shares Held (W) Percentage Held (%)
1 UBS AG QFII 174.99 0.64
2 CITIC Securities Asset Management (Hong Kong) Limited - Client Funds Asset Management Plan 148.38 0.54
3 J. P. Morgan Securities PLC - Proprietary Funds QFII 138.06 0.50
4 Goldman Sachs & Co. LLC QFII 95.80 0.35

5. Concept Sectors

  • Venture Capital Concept
  • Biological Vaccine
  • Assisted Reproduction
  • Hepatitis Concept
  • Innovative Drug
  • Non-Recurring Loss

Remarks

  • Data update date: 2026-01-01
  • Data source: Public Market Information